IIA Bio-Convergence

IIA Bio-Convergence sits under the Israel Innovation Authority as a dedicated grant track for projects that sit at the intersection of biology and digital technology, including machine learning, materials, and devices. The structured record puts the program in Israel, marks it active, and sets the award range at USD 500,000 to USD 3 million. Its stated purpose is to back emerging bio-tech work that crosses disciplines rather than staying inside a single technical lane. The program runs on an annual cadence with Israeli registration and operations. Funding can cover up to 50 percent of R&D costs, which makes the track materially different from a full-cost subsidy and keeps applicants responsible for a meaningful share of project spending. Individuals are excluded, and the public record keeps the program focused on organized entities that can execute multi-year technical work. The practical fit is a company that can connect biology to software, data, materials, or medical-device development without losing the product path. Projects are stronger when the bio piece is not decorative and the non-bio piece is not incidental; the track is built for genuine convergence. For applicants, the clearest case is a team that can show why the combined stack advances a commercial or clinical technology in Israel and why the project needs cross-disciplinary support to move forward.

No upcoming rounds verified. Cadence: Annual.